JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB259006

Human NT5C3A (PN-I) knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

NT5C3A KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon5.

View Alternative Names

5NT3A_HUMAN, Cytosolic 5' nucleotidase 3, Cytosolic 5' nucleotidase III, Cytosolic 5''-nucleotidase 3, Cytosolic 5''-nucleotidase 3A, Cytosolic 5''-nucleotidase III, NT5C3, Nt5c3a, P5''N-1, P5'N 1, P5N-1, PN-I, Pyrimidine 5' nucleotidase 1, Pyrimidine 5''-nucleotidase 1, UMPH, UMPH1, Uridine 5' monophosphate hydrolase 1, Uridine 5''-monophosphate hydrolase 1, cN-III, p36

1 Images
Sanger Sequencing - Human NT5C3A (PN-I) knockout A549 cell lysate (AB259006)
  • Sanger seq

Unknown

Sanger Sequencing - Human NT5C3A (PN-I) knockout A549 cell lysate (AB259006)

Homozygous : 1 bp insertion in exon5

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon5.

Disease

Carcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab259006-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human NT5C3A knockout A549 cell lysate", "number":"AB259006-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB259006-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
NT5C3A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PN-I commonly known as Protease Nexin I serves as a serine protease inhibitor. It has a molecular mass of approximately 43 kDa. PN-I expression occurs predominantly in the nervous system and various cell types such as fibroblasts and endothelial cells. It regulates the activity of multiple proteases like thrombin urokinase and plasminogen activator. This regulation helps to ensure a balance in protease activity.
Biological function summary

PN-I plays a significant role in maintaining extracellular matrix homeostasis and modulating cellular processes like migration and proliferation. It is part of a complex with proteases that it inhibits forming stable complexes to neutralize their activity. Through its actions PN-I influences cell signaling and tissue remodeling having effects that are essential for physiological processes.

Pathways

PN-I interacts with the fibrinolytic and coagulation pathways. It modulates these pathways by inhibiting enzymes such as thrombin and urokinase impacting processes like blood clot formation and degradation. In the coagulation cascade PN-I effects relate closely to proteins like thrombin affecting blood homeostasis and ensuring a proper response to vascular injury.

PN-I has links to conditions such as thrombosis and tissue fibrosis. Alterations in PN-I expression or function can contribute to pathological states by disrupting protease regulation leading to excessive clot formation or tissue scarring. PN-I interacts with proteins involved in these diseases such as plasminogen activators highlighting its importance in maintaining proteolytic balance in tissues.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com